Contrarian Value Ideas

[gfp927z]

TEVA getting demolished, now down near 20 from its high of over 70 in 2015. I figured they'd probably have to cut their dividend eventually, considering the $35 billion in debt on the balance sheet from the big acquisition of Actavis last year. They paid a whopping $41 bil, and just as the generics landscape began to go south. Meanwhile Teva's proprietary Copaxone franchise lost its patent protection, so the company's profitability got hit from all sides.